Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Beverley Davies who wrote (415)	6/12/1998 4:01:00 PM
From: Gwolf	Read Replies (1) \| Respond to of 5402

Thanks I didn't catch the misspelling. Treat - pleasure or whatever you want to call in. The bottom line is he will come away very informed on the the technology and the potential for the company. Gwolf

To: Beverley Davies who wrote (415)	6/12/1998 5:37:00 PM
From: Prospector	Read Replies (1) \| Respond to of 5402

Bev Blood Substitute Competition Three of Sanguine's probable competitors in the blood substitute race have suffered serious setbacks. In July 1996, Pharmacia Upjohn backed out of their joint venture with Biopure who are using cow's blood in their attempt to make a blood substitute. In March 1997, Somatogen's pharmaceutical partner, Eli Lilly, withdrew from their joint DNA blood project. In April, 1997 Alliance Pharmaceutical suspended their LiquiVent clinical trials because the mortality rate of the control groups deceased; in other words, their project was not effective. On May 6,1997, Baxter International reported that their blood substitute, HemAssist, Was doing better, Although only 39% of the cardiac surgery patients needed human blood and infused only 209 patients, instead of the usual 850 or more. Baxter's report seems to be P.R. damage control in the face of these other failures. On May 22, 1997, Northfield Laboratories reported that their blood substitute, PolyHeme, in clinical trials, significantly reduced the need for the blood transfusions in hemorrhaging trauma patients.. Only one hundred patients were involved in this clinical trial. Sanguines synthetic blood is entirely different for our competitor's products. Baxter and Northfield use outdated human blood which is in short supply. Somatogen also uses outdated human blood but its manufacturing processes make their products, Optro very expensive. Cow blood (Biopure) is plentiful but has the problem of AIDS and MAD Cow disease. Snaguine's product,PHER-02, is improved second generation product of the only FDA approved blood substitute. The raw materials are low cost and supply is plentiful. Thomas C. Drees Prospector